TR201904760T4 - İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler. - Google Patents

İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler. Download PDF

Info

Publication number
TR201904760T4
TR201904760T4 TR2019/04760T TR201904760T TR201904760T4 TR 201904760 T4 TR201904760 T4 TR 201904760T4 TR 2019/04760 T TR2019/04760 T TR 2019/04760T TR 201904760 T TR201904760 T TR 201904760T TR 201904760 T4 TR201904760 T4 TR 201904760T4
Authority
TR
Turkey
Prior art keywords
methods
inflammation
diseases associated
eye diseases
vascular proliferation
Prior art date
Application number
TR2019/04760T
Other languages
English (en)
Inventor
James Kelly Darren
Stapleton David
Original Assignee
Occurx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905197A external-priority patent/AU2010905197A0/en
Application filed by Occurx Pty Ltd filed Critical Occurx Pty Ltd
Publication of TR201904760T4 publication Critical patent/TR201904760T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Süjelerde infalamasyon ve/veya vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler açıklanmaktadır. Yöntemler, terapötik olarak yeterli miktarlarda bir tranilast bileşiğinin, özellikle (E)-2-[[3-(3-Metoksi-4-propargiloksi)fenil)-1-okso-2-propenil]amino]benzoik asit veya (E)-2-[[3,4-Bis(diflorometoksi)fenil)-1-okso-2-propenil]amino]benzoik asit veya bunların farmasötik olarak kabul edilebilir tuzları veya solvatlarını kapsamaktadır.
TR2019/04760T 2010-11-24 2011-11-10 İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler. TR201904760T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2010905197A AU2010905197A0 (en) 2010-11-24 Methods of treating eye diseases associated with inflammation and vascular proliferation

Publications (1)

Publication Number Publication Date
TR201904760T4 true TR201904760T4 (tr) 2019-04-22

Family

ID=46145280

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04760T TR201904760T4 (tr) 2010-11-24 2011-11-10 İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler.

Country Status (21)

Country Link
US (5) US9839640B2 (tr)
EP (2) EP2642989B1 (tr)
JP (1) JP5942131B2 (tr)
KR (1) KR101899613B1 (tr)
CN (1) CN103228275B (tr)
AU (1) AU2011334592C1 (tr)
CA (1) CA2815390C (tr)
DK (2) DK3485883T3 (tr)
ES (2) ES2829620T3 (tr)
HR (1) HRP20190561T1 (tr)
HU (1) HUE042676T2 (tr)
MX (1) MX352517B (tr)
NZ (1) NZ609144A (tr)
PL (1) PL2642989T3 (tr)
PT (1) PT2642989T (tr)
RS (1) RS58603B1 (tr)
SG (1) SG189326A1 (tr)
SI (1) SI2642989T1 (tr)
TR (1) TR201904760T4 (tr)
WO (1) WO2012068612A1 (tr)
ZA (1) ZA201302638B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2642989T3 (pl) 2010-11-24 2019-07-31 Occurx Pty Ltd Sposoby leczenia chorób oczu związanych z zapaleniem i proliferacją naczyniową
WO2018144620A1 (en) 2017-02-03 2018-08-09 Shire Human Genetic Therapies, Inc. Anti-fibrotic compounds
CN110357789B (zh) * 2018-04-11 2022-09-30 华东理工大学 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
KR20230024331A (ko) * 2020-06-05 2023-02-20 오쿠렉스 피티와이 리미티드 눈 장애의 치료를 위한 화합물 및 방법
IL305480A (en) * 2021-03-17 2023-10-01 Occurx Pty Ltd Compounds for the treatment of disorders and their salts and polymorphs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09176003A (ja) 1995-12-28 1997-07-08 Tsumura & Co 角膜治療剤
EA199800721A1 (ru) 1996-02-15 1999-02-25 Киссеи Фармасьютикал Ко., Лтд. Ингибитор реваскуляризации
JPH09278653A (ja) 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
JPH10259129A (ja) * 1997-01-16 1998-09-29 Kissei Pharmaceut Co Ltd 血管新生阻害剤
DE69814612T2 (de) 1997-02-14 2004-03-11 Kissei Pharmaceutical Co., Ltd., Matsumoto Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
JPH10330254A (ja) 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US20070254055A1 (en) 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
JP4966019B2 (ja) 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
KR101565271B1 (ko) 2006-07-05 2015-11-02 피브로테크 세라퓨틱 피티와이 엘티디 치료 화합물
WO2008131481A1 (en) * 2007-04-26 2008-11-06 Fibrotech Therapeutics Pty Ltd Treatment of mesangioproliferative diseases
KR20100047860A (ko) 2007-07-06 2010-05-10 누온 테라피우틱스, 아이엔씨. 신경병증 통증의 치료
US8624056B2 (en) * 2007-12-21 2014-01-07 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
US20100158905A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
EP2491030B1 (en) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
PL2642989T3 (pl) 2010-11-24 2019-07-31 Occurx Pty Ltd Sposoby leczenia chorób oczu związanych z zapaleniem i proliferacją naczyniową

Also Published As

Publication number Publication date
US20180117051A1 (en) 2018-05-03
US20180117050A1 (en) 2018-05-03
EP3485883A1 (en) 2019-05-22
MX352517B (es) 2017-04-06
US10786510B2 (en) 2020-09-29
US10695353B2 (en) 2020-06-30
ES2722723T3 (es) 2019-08-16
MX2013005561A (es) 2014-11-10
DK3485883T3 (da) 2020-10-12
CN103228275A (zh) 2013-07-31
SI2642989T1 (sl) 2019-07-31
EP2642989B1 (en) 2019-01-02
PL2642989T3 (pl) 2019-07-31
RS58603B1 (sr) 2019-05-31
CA2815390C (en) 2021-07-13
JP2014502267A (ja) 2014-01-30
ZA201302638B (en) 2023-07-26
KR101899613B1 (ko) 2018-09-17
NZ609144A (en) 2014-08-29
AU2011334592A1 (en) 2013-05-02
WO2012068612A1 (en) 2012-05-31
HUE042676T2 (hu) 2019-07-29
ES2829620T3 (es) 2021-06-01
EP2642989A1 (en) 2013-10-02
US11583535B2 (en) 2023-02-21
SG189326A1 (en) 2013-05-31
US20130310386A1 (en) 2013-11-21
HRP20190561T1 (hr) 2019-06-14
AU2011334592C1 (en) 2015-04-02
AU2011334592B2 (en) 2014-10-23
JP5942131B2 (ja) 2016-06-29
DK2642989T3 (en) 2019-04-15
US20210244741A1 (en) 2021-08-12
US9839640B2 (en) 2017-12-12
EP2642989A4 (en) 2014-09-24
PT2642989T (pt) 2019-04-23
EP3485883B1 (en) 2020-08-26
US20180117049A1 (en) 2018-05-03
CN103228275B (zh) 2016-08-10
CA2815390A1 (en) 2012-05-31
KR20140012032A (ko) 2014-01-29

Similar Documents

Publication Publication Date Title
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
MA33939B1 (fr) 5-alcynyl-pyrimidines
NI201200072A (es) Métodos y composiciones para tratar cáncer
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
MX2012011504A (es) Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
MX2009013332A (es) Inhibidores de ire-1 alfa.
PH12014501277A1 (en) Kinase inhibitors
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
TR201907804T4 (tr) Apaf-1 inhibitör bileşikleri.
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
IN2015DN04175A (tr)
TR201904760T4 (tr) İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler.
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201100255A1 (ru) 5-алкинилпиримидины
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
AU2012228355A8 (en) N-(1,2,5-oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides and their use as herbicides
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12014501278A1 (en) Kinase inhibitors
TW201129554A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
WO2012158672A3 (en) Compounds for use in treatment of mucositis